MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma (MARS2)

Primary Outcome Measures:

Ability to randomise 50 patients [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Ability to randomise 50 patients within the first 24 months or the ability to recruit 25 patients within any 6 month period

Secondary Outcome Measures:

Survival from the time point of randomisation [ Time Frame: Follow up for up to 5 years ] [ Designated as safety issue: Yes ]

Quality of life as assessed using QLQ 30 and LC-13 scales [ Time Frame: Follow up for up to 5 years ] [ Designated as safety issue: No ]

Eligibility Criteria

Inclusion Criteria:

1. Histological confirmation of mesothelioma, 2. Disease confined to one hemi-thorax.

Exclusion Criteria:

1. Unable to give informed consent,
2. Patients unwilling to be randomised,
3. Extent of disease not deemed to be surgically resectable,
4. ECOG status 2 or more,
5. Patients with predicted pre-operative FEV1 or TLco less than 20%,
6. Patients with severe heart failure (EF less than 30%),
7. Patients with end stage kidney failure requiring dialysis,
8. Patients with liver failure,
9. Patients who are participating in another interventional clinical trial.